

$\frac{1}{2}$ 1 **ARTICLE HIGHLIGHTS**
2 Type of Research:

2 **Type of Research:**

- 3 Single-center prospective cohort study
-

4

- **Key Findings:**
6 25 subjects with symptomatic PAD underwent open or
- 6 25 subjects with symptomatic PAD underwent open or
7 endovascular lower extremity revascularization in a sm. 9 endovascular lower extremity revascularization in a small
8 cohort. Smaller apo(a) isoforms were associated with
- 8 cohort. Smaller apo(a) isoforms were associated with
9 occlusion of the treated lesion(s) within 2-4 weeks
-
- 10 [OR=1.97 (95% CI 1.01 3.86, p<0.05)], suggesting
- 10 [OR=1.97 (95% CI 1.01 3.86, p<0.05)], suggesting
11 apo(a) isoform size as a predictor of primary patency 11 apo(a) isoform size as a predictor of primary patency in
12 the early period after lower extremity intervention.
- 12 the early period after lower extremity intervention.
13
-

13

- **Take Home Message:**
15 Subjects with high Lp(a) levels, generally have smaller
- 16 $apo(a)$ isoform sizes. We find that, in this small cohort,
- 17 patients undergoing peripheral arterial revascularization
- 18 subjects with small isoforms are at an increased risk of 18 subjects with small isoforms are at an increased risk of
19 treated vessel occlusion in the perioperative period.
- 19 treated vessel occlusion in the perioperative period.
20

20
21

- 21 **Table of Contents Summary**
22 Subjects with symptomatic PAD requiring lower
- 22 Subjects with symptomatic PAD requiring lower
23 extremity revascularization have high median Lp 23 extremity revascularization have high median $Lp(a)$
23

21 genome wide association studies (GWAS)⁻¹. Elevated Lp(a) levels are independently associated
22 with incidence of major adverse cardiovascular events (MACE) and major adverse limb events

22 with incidence of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after lower extremity endovascular 2 or open surgery 3 while controlling for other risk

(ABALEAR)] between June 2018 and March 2021, **Supplemental Figure 2**. The study protocol

 $\overline{7}$

 \overline{a} 1 was approved by the CUIMC Institutional Review Board (AAAL7756). Inclusion criteria
2 encompassed adult subjects with a clinical diagnosis of PAD, who were planned to undergo non-3 emergent revascularization (open or endovascular) of the affected lower extremity. Those with 4 ischemic wounds, active infectious process, or cardiovascular intervention within 12 months of 5 enrollment were excluded. Two of the participants who underwent only diagnostic angiogram 5 enrollment were excluded. Two of the participants who underwent only diagnostic angiogram
6 were also excluded from final analysis. The type of intervention was at the discretion of the 6 were also excluded from final analysis. The type of intervention was at the discretion of the treating provider. 7 treating provider.
8

8 9 *Recruitment/Enrollment:* Subjects that met inclusion and exclusion criteria were contacted prior
10 to their scheduled operation and informed consent was obtained. Medical and social history were 10 to their scheduled operation and informed consent was obtained. Medical and social history were
11 collected by a licensed health professional, including demographic information (age, sex, self-11 collected by a licensed health professional, including demographic information (age, sex, self-
12 reported race-ethnicity (SRRE)), history of smoking, hypertension (HTN), diabetes, carotid 12 reported race-ethnicity (SRRE)), history of smoking, hypertension (HTN), diabetes, carotid
13 artery disease (CAD) or dyslipidemia. Medication use [antihypertensives, statins, antiplatelet 14 (AP), direct oral anticoagulant (DOAC)] and symptoms of rest pain or claudication (ambulatory 15 distance in city blocks) were recorded. A pre-operative physical exam was performed, which 16 included distal pulses, a lower extremity arterial duplex ultrasound (US), ankle brachial index 16 included distal pulses, a lower extremity arterial duplex ultrasound (US), ankle brachial index
17 (ABI), and body mass index (BMI). On the day of the surgical procedure, arterial blood sampl 17 (ABI), and body mass index (BMI). On the day of the surgical procedure, arterial blood samples
18 were collected using EDTA tubes; plasma was separated and stored at -80 °C. 18 were collected using EDTA tubes; plasma was separated and stored at −80◦C.
19

20 20 *Study Follow-up (2-4 weeks and 3-6 months):* Participants were seen in the office for their post-
21 operative visits by their respective providers. During these visits, physical exam (pulses, US, 21 operative visits by their respective providers. During these visits, physical exam (pulses, US,
22 ABIs) to assess for primary patency and the trajectory of self-reported subjective symptoms v 22 ABIs) to assess for primary patency and the trajectory of self-reported subjective symptoms were
23 determined based on presence or resolution of rest pain and changes in walking distance. These 23 determined based on presence or resolution of rest pain and changes in walking distance. These

8

13
14

14 Plasma Lp(a), apoB100, lipids [triglycerides (TG), total cholesterol(C), high density lipoprotein
15 (HDL)] were automatically measured on Integra 400 plus (Roche). Plasma LDL-C levels were 16 calculated using the Friedewald formula (one subject had a TG level >400 mg/dL and was not 16 calculated using the Friedewald formula (one subject had a TG level >400mg/dL and was not
17 reported). Plasma apoB100 levels were measured by a human enzyme-linked immunosorbent 17 reported). Plasma apoB100 levels were measured by a human enzyme-linked immunosorbent
18 assay (ELISA) from Mabtech, Inc, Cincinnati, OH. Lp(a) plasma concentration were measured 18 assay (ELISA) from Mabtech, Inc, Cincinnati, OH. Lp(a) plasma concentration were measured
19 using the isoform-independent sandwich ELISA developed by the Northwest Lipid Metabolism 20 and Diabetes Research Laboratory at Medpace, Inc. Apo(a) isoform size measurements were 21 performed by the same laboratory using agarose gel electrophoresis. ChemiDoc MP Imaging 22 System was used to determine the isoforms using in-house standards and relative expression of 22 System was used to determine the isoforms using in-house standards and relative expression of
23 each isoform was reported. Weighted isoform size (wIS) was calculated using the % isoform 23 each isoform was reported. Weighted isoform size (*wIS*) was calculated using the % isoform

20 published studies of surgical outcomes 22 25 . We did not control for history of CAD, as literature
21 shows that most individuals with diagnosis of PAD have some degree of CAD and at least 60% 21 shows that most individuals with diagnosis of PAD have some degree of CAD and at least 60% have significant CAD^{24} .

22 have significant CAD^{24} .
23

10

$\overline{\mathbf{I}}$

1 **Results** 2 *Baseline Characteristics*: Subject demographics, lipid and lipoprotein levels are shown in **Table** 1 **I**. The study population included 12 females and 13 males with a mean age of 66.7±9.7 years.
4 Our cohort was multiethnic with 8 Blacks, 5 Hispanics, and 12 Whites, representative of the 5 available population at our institution. All subjects were Rutherford stage 3 and 4.5 subjects 6 underwent open revascularization and 20, endovascular. Majority of the subjects underwent 6 underwent open revascularization and 20, endovascular. Majority of the subjects underwent

7 infra-inguinal intervention ($N=23$) and 6 required re-intervention within 3-6 months. Individe 7 infra-inguinal intervention (N=23) and 6 required re-intervention within 3-6 months. Individuals
8 were mildly overweight and lipid levels consistent with a population being treated for 8 were mildly overweight and lipid levels consistent with a population being treated for
9 dyslipidemia. Despite use of lipid lowering therapies, the mean apoB100 levels were $168.0 \pm$ 10 65.8 mg/dL. Median plasma Lp(a) level was 108 (44, 301) nmol/L. Primary patency rates at $2-4$ 10 65.8 mg/dL. Median plasma Lp(a) level was 108 (44, 301) nmol/L. Primary patency rates at 2-4
11 weeks and 3-6 months were 76% and 68%. Rate of re-intervention measured at 3–6-months visit 11 weeks and 3-6 months were 76% and 68%. Rate of re-intervention measured at 3–6-months visit
12 was 24%. 12 was 24%.

14 14 *Lp(a) levels and Isoform Size:* Previous reports show that high Lp(a) levels are associated with
15 worse outcomes after surgical intervention. We found that most of the individuals in our cohort 16 had high Lp(a) levels. The mean wIS was 18.4 ± 4.1 and as expected, there was an inverse 16 had high Lp(a) levels. The mean *wIS* was 18.4 ± 4.1 and as expected, there was an inverse
17 relationship between Lp(a) levels and *wIS* ($R^2 = 0.20$; p=0.02), **Figure 1**. Most individuals 17 relationship between Lp(a) levels and wIS ($R^2 = 0.20$; p=0.02), **Figure 1**. Most individuals
18 express two apo(a) isoforms, however in our small diverse cohort, we found that half (N=12) 18 express two apo(a) isoforms, however in our small diverse cohort, we found that half (N=12)
19 individuals expressed only a single isoform, **Supplemental Table I**, with predominance of the 19 individuals expressed only a single isoform, **Supplemental Table I**, with predominance of the small isoform, **Figure 2.** 20 small isoform, **Figure 2.**

22 22 *Relationship of Lp(a) levels and Isoforms with surgical outcomes:* We did not find significant
23 associations between Lp(a) levels and post-surgical symptoms, ABI, primary patency, or re-23 associations between $Lp(a)$ levels and post-surgical symptoms, ABI, primary patency, or re-

- 23
-

$\overline{\mathbf{a}}$

1 Discussion
2 **High Lp(a)** levels are associated with adverse limb events in patients with symptomatic PAD 2 High Lp(a) levels are associated with adverse limb events in patients with symptomatic PAD undergoing lower extremity revascularization 25×26 2. International guidelines (Canadian 27 and 3 undergoing lower extremity revascularization 25,26 $\frac{2}{3}$. International guidelines (Canadian 27 and ECC 28) advocate for all individuals to have Lp(a) measured once in a lifetime. In the United ECC²⁸) advocate for all individuals to have Lp(a) measured once in a lifetime. In the United
States, the American Heart Association (AHA) suggest using Lp(a) levels as a 'risk enhancer⁻²⁹.
However, there are no specif 6 However, there are no specific guidelines for Lp(a) measurements in patients with advanced
7 PAD that are referred for surgical intervention. All subjects in our study have been diagnosed PAD that are referred for surgical intervention. All subjects in our study have been diagnosed
8 with at least one metabolic disease, however, they were not screened for $Lp(a)$ by their primar 8 with at least one metabolic disease, however, they were not screened for $Lp(a)$ by their primary
9 providers; and the majority were found to have elevated levels. 9 providers; and the majority were found to have elevated levels.
10 11 11 Although our study sample is small, which limits the generalizability of the results, it features a
12 good representation based on gender and race. These data can be used to develop well controlled 13 cross-sectional studies that can examine the role of apo(a) in larger populations with PAD. Most 14 individuals at risk or that have ASCVD, obtain laboratory measurement of low-density 15 lipoprotein cholesterol (LDL-C), an apoB100 containing particle. Physicians rely on these 16 measurements for prescribing lipid therapies, such as statins, in clinical practice. We observed 17 that in our cohort, 76% of individuals were prescribed statins. While statins significantly lower that in our cohort, 76% of individuals were prescribed statins. While statins significantly lower
18 LDL-C, they tend to increase $Lp(a)$ by about 11% ¹. It is important to note, however, that the LDL-C, they tend to increase Lp(a) by about 11%⁻¹. It is important to note, however, that the laboratory levels of LDL-C in plasma are known to be confounded by the presence of Lp(a)-C³⁰, which contains both apoB100 a 20 which contains both apoB100 and apo(a). The reason for this overlap lies in similar plasma
21 densities between $Lp(a)$ and LDL particles. Thus, in patients with high levels of $Lp(a)$ the actual 22 LDL-C is lower from the reported value and some investigators believe apoB100 to be a more 22 LDL-C is lower from the reported value and some investigators believe apoB100 to be a more accurate measure of cardiovascular risk compared to LDL- C^{31} . This is important, because most accurate measure of cardiovasc

 \overline{a} 1 levels, the predictive association of *wIS* with primary patency was still statistically significant.
2 Although data in the literature regarding disease predictability of Lp(a) vs apo(a) is conflicting, 3 there is evidence that the strength of the association is higher for apo(a) is of orm size in certain 3 there is evidence that the strength of the association is higher for apo(a) isoform size in certain
4 diseases³⁴. To our knowledge, there are no reports assessing the correlation between apo(a) size 4 diseases³⁴. To our knowledge, there are no reports assessing the correlation between apo(a) size
3 and primary patency. Our preliminary study finds that small apo(a) size strongly correlates with 6 primary patency within 2-4 weeks with a trend towards a higher rate or re-intervention at $3-6$ 6 primary patency within 2-4 weeks with a trend towards a higher rate or re-intervention at 3-6
7 months. Although more comprehensive evaluation of the prognostic relationship between apo 7 months. Although more comprehensive evaluation of the prognostic relationship between apo(a)
8 size and these outcomes of peripheral arterial interventions would be served in a randomized or 8 size and these outcomes of peripheral arterial interventions would be served in a randomized or
9 cross-sectional study, these results support what is already known about apo(a)'s mode of action. 10 We postulate that the probable mechanisms lie in the apo(a)'s kringle structure having homology 11 with fibrinolytic proenzyme plasminogen, but inactive in fibrinolysis. Small apo(a) is of orm size 11 with fibrinolytic proenzyme plasminogen, but inactive in fibrinolysis. Small apo(a) isoform size
12 resulting from low *LPA* KIV-2 number of repeats can slow fibrinolysis and thus indirectly 12 resulting from low *LPA* KIV-2 number of repeats can slow fibrinolysis and thus indirectly
13 promote thrombosis, leading to increased risk of perioperative complications such as graft 13 promote thrombosis, leading to increased risk of perioperative complications such as graft
14 occlusion or thromboembolic events ³⁵. Additionally, apo(a) potentiates thrombosis by bine 14 occlusion or thromboembolic events 35 . Additionally, apo(a) potentiates thrombosis by binding and inactivating tissue factor pathway inhibitor (TFPI)³⁶. This is especially important, as many 15 and inactivating tissue factor pathway inhibitor (TFPI)³⁰. This is especially important, as many
16 of peripheral arterial intervention are performed to aid in wound healing and this period may be 16 of peripheral arterial intervention are performed to aid in wound healing and this period may be
17 imperative for patients with tissue loss. These pro-thrombotic action of the apo(a) could also 17 imperative for patients with tissue loss. These pro-thrombotic action of the apo(a) could also
18 explain the high rate of early re-intervention in this cohort of patients with high $Lp(a)$, 18 explain the high rate of early re-intervention in this cohort of patients with high Lp(a),
19 particularly as 5 our 6 subjects in the group requiring re-intervention had small apo(a), 19 particularly as 5 our 6 subjects in the group requiring re-intervention had small apo(a),
20 **Supplemental Figure 1.** 20 **Supplementa**l **Figure 1.** 22 22 A study from a UK biobank studied approximately $460\degree$ thousand participants and showed
23 significant differences in Lp(a) concentrations across racial subgroups, specifically with hig

significant differences in $Lp(a)$ concentrations across racial subgroups, specifically with higher

21 Further research in larger cohorts is needed to establish a more robust understanding of the
22 mechanisms and impact of apo(a) isoform size on surgical outcomes in patients PAD. mechanisms and impact of apo(a) isoform size on surgical outcomes in patients PAD.

17

4

1 Study Limitations
1 Overall, this was a sample of convenience. Subject samples and prospectively collected data 6 from ongoing biomarker study (ABALEAR) were available to our lipid team to examine 6 from ongoing biomarker study (ABALEAR) were available to our lipid team to examine
7 additional affecters on surgical outcomes. Although subject baseline characteristics are 7 additional affecters on surgical outcomes. Although subject baseline characteristics are
8 comparable to larger cohorts, we acknowledge that sample size is small and significantl 8 comparable to larger cohorts, we acknowledge that sample size is small and significantly limit
9 the generalizability of the results. We used firth logistics regression to account for small sample 10 size. Additionally, the cohort is heterogenous in terms of presenting symptoms with surgical 10 size. Additionally, the cohort is heterogenous in terms of presenting symptoms with surgical
11 interventions geared towards each patient's needs, but ultimately 'no leg is alike,' and the col 11 interventions geared towards each patient's needs, but ultimately 'no leg is alike,' and the cohort
12 represents a diverse spectrum of lower extremity disease and intervention seen in vascular 12 represents a diverse spectrum of lower extremity disease and intervention seen in vascular
13 surgery clinics. Additionally, due to limited size, associations between peripheral intervent 13 surgery clinics. Additionally, due to limited size, associations between peripheral interventions
14 and Lp(a) levels/apo(a) size was done without correction for multiple testing. 14 and $Lp(a)$ levels/apo(a) size was done without correction for multiple testing.
15

15

Conclusion
17 In this limited cohort, most subjects with chronic symptomatic PAD had elevated Lp(a) levels 18 without being screened by their medical providers outside of the study, pointing to the need to 19 increase awareness for $Lp(a)$ screening in vascular patients. Small apo(a) isoform expression 20 could be an important risk predictor not only for the development of PAD, which has already 20 could be an important risk predictor not only for the development of PAD, which has already
21 been established in literature, but also as a driver of worse short term surgical outcomes. Furth 21 been established in literature, but also as a driver of worse short term surgical outcomes. Further
22 studies identifying the mechanism and relationship of these findings to long-term peripheral 22 studies identifying the mechanism and relationship of these findings to long-term peripheral

- $\frac{1}{\pi}$ \overline{a} 1 vascular outcomes are warranted, specifically identifying the role of apo(a) size among different
2 sexes and races in larger well controlled cohorts.
- 2 sexes and races in larger well controlled cohorts.
-

- 4 **Acknowledgements**
5 We would like to acknowledge Anastasiya Matveyenko¹and Srinivas Cherukuri¹ 5 We would like to acknowledge Anastasiya Matveyenko¹ and Srinivas Cherukuri¹ for their
6 assistance with study conduction and laboratory measurements. **Funding** for this study was
-
- 7 provided by T32HL007343 (M.P.), UL1TR001873 (G.R.S), partial funding for MP stipend and
- 7 provided by T32HL007343 (M.P.), UL1TR001873 (G.R.S), partial funding for MP stipend and
8 manuscript processing funds were supported by a donation from Robin Chemers Neustein to the 8 manuscript processing funds were supported by a donation from Robin Chemers Neustein to the
9 Reyes-Soffer Laboratory.
- 9 Reyes-Soffer Laboratory.

19

$\overline{\mathbf{I}}$

-
- 1 **References** 3
4
5 3 1. DM, Marcovina SM, Yeang C, Koschinsky ML, et al. Lipoprotein(a): A Genetically
5 2. Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascula
6 2. Disease: A Scientific Statement From the America 5 Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular
6 Disease: A Scientific Statement From the American Heart Association. Arterioscler
7 Thromb Vasc Biol. 2022;42:e48-e60. Disease: A Scientific Statement From the American Heart Association. Arterioscler 6 Bisease: A Scientific Statement From the American Heart Association. Arterioscler
7 Thromb Vasc Biol. 2022;42:e48-e60.
8 2. Tomoi Y, Takahara M, Soga Y, Kodama K, Imada K, Hiramori S, Ando K. Impact of H 7 Thromb Vasc Biol. 2022, 42: e40 e60.
8 2. Tomoi Y, Takahara M, Soga Y, Kodam
9 Lipoprotein(a) Levels on Clinical Outo 8 2. Tomoi Y, Takahara M, Soga Y, Kodama K, Imada K, Hiramori S, Ando K. Impact of High
19 Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy.
10 JA*CC Cardiovasc Interv*. 2022;15:1466-147 9 Jacc Cardiovasc Interv. 2022;15:1466-1476. doi: 10.1016/J.jcin.2022.05.050
1 3. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J, Hazenberg 10 10 JACC Cardiovasc *Interv.* 2022,15:1466-1476. doi: 10.1016/j.jcin.2022.05.050
11 3. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J,
12 C, de Kleijn DPV. High lipoprotein(a) is associated wit 11 3. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J, Hazenberg
12 C, de Kleijn DPV. High lipoprotein(a) is associated with major adverse limb events after
13 femoral artery endarterectomy. Ather 13 femoral artery endarterectomy. Atherosclerosis. 2022;349:196-203. doi:
14 10.1016/j.atherosclerosis. 2021.11.019 15 4. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and 16 Emerging Therapies. J Am Coll Cardiol. 2017;69:692-711. doi: 10.1016/j.jacc.2016.11.042 17 5. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger 16 Emerging Therapies. J Am Coll Cardiol. 2017, 09.092-711. doi: 10.1010/j.jacc.2010.11.042
17 5. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger
18 S, Oberhollenzer F, et al. Oxid 17 5. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger 18 S, Oberhollenzer F, et al. Oxidized phospholipids predict the presence and progression
19 of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-
20 year prospective results from the Bruneck doi: 10 1016/j.jacc.2006.03.001 20 year prospective results from the Bruneck study. J Am Coll Cardiol. 2000, 47:2219-2220.
21 doi: 10.1016/j.jacc.2006.03.001
22 6. Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements: 22 6. Reyes-Soffer G, Westerterp M. E
23 Lipoprotein(a) and inflammation 22 6. Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurem
23 Lipoprotein(a) and inflammation. *Pharmacol Res*. 2021;169:105689. doi:
24 10.1016/j.phrs.2021.105689 23 Lipoprotein(a) and inflammation. *Pharmacol Res. 2021*, 109.109009. doi:
24 10.1016/j.phrs.2021.105689
25 7. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, al 24 10.1016/j.phrs.2021.105689 25 7. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and a lipoprotein (a). *J Lipid Res.* 2016;57:1339-1359. doi: 10.1194/jlr.R067314
27 8. Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogue Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated 28 1ipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic (29 11 and 2022; 27:385-391. doi: 10.1177/1358863X221091320
19. Marbagelata Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmave Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, 25 review. *Vasc Med. 2022,21:385-331.* doi: 10.1177/1358883X221091320
30 9. Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltma
31 Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations 31 9. Dieplinger B, Lingenheit V, Baumgartner N, Poelz W, Pieplinger M, Hamme, 2007,
31 9. Monenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and lov
32 9. Molecular weight phenotypes of apolipoprotein(a 31 Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low
32 molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic
33 peripheral arterial disease. *Clin Chem*. 2007;53:129 peripheral arterial disease. Clin Chem. 2007;53:1298-1305. doi: 33 peripheral arterial disease. C*lin Chem. 2007*,33:1298-1305. doi:
34 10.1373/clinchem.2007.088013
35 10. Molgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olss 2007.
35 10. Molgaard J, Klausen IC, Lassvik C
36 35 association between low-molecu 35 10. Molgammy, Marisson J, Ensign, Programmy, School 21, 2006.
35 10. Molgammy association between low-molecular-weight apolipoprotein(a) isoforms and interm
37 10. Molgammy and Claudication. Arterioscler Thromb. 1992; 1 37 association between the molecular-weight apolipoprotein(a) isotomic and intermittent
38 as 11. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) claudication. Arterioscler Thromb. 1992;12:895-901. doi: 10.1161/01.atv.12.8.895
38 11. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a)
39 level and apolipoprotein(a) phenotype as predicto 39 12. Evel and apolipoprotein(a) phenotype as predictors of long-term cardiovascular
10 11. outcomes after coronary artery bypass grafting. A*therosclerosis*. 2014;235:477-482. d 39 decompose outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235:477-4.
41 10.1016/j.atherosclerosis. 2014.05.944 41 outcomes after after coronary artes after and the coronary artery arter coronary artering. 42
42 degrafting. Ather consisted M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S, 42 12. Kandelouei T, Abbasifard M, Imani D, A
43 Mohammadi K, Jamialahmadi T, Reiner 43 12. Mohammadi K, Jamialahmadi T, Reiner Z, et al. Effect of Statins on Serum leve
44 12. CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review ar

1

Table I. Baseline characteristics, lipid, and lipoprotein levels

Legend: ± represents Mean and Standard Deviation; () represents Median and Interquartile Range.

2

*Calculated LDL-C means reported for N=24, one subject had >400 mg/dL TG levels (Supplemental Table I). Coronary artery disease (CAD); direct oral anticoagulant (DOAC), antiplatelet (AP), dual antiplatelet therapy (DAPT)

Table IIa. Effects of apo(a) *wIS* on surgical outcomes

Table IIb. Effects of Lp(a) on surgical outcomes

Legend: PAD: Peripheral Arterial Disease; *wIS*: weighted Isoform Size; Δ ABI: change in Ankle Brachial Index; Δ Symptoms: change in symptoms, *wIS* and Lp(a) were standardized, *statistical significance = p < 0.05; Firth model: exponential estimate (95% CI). Available number of subject data for each outcome (N=X) are provided. Complete ABI data is missing in 11 subjects

Marker	PAD Cohort	<i>*Healthy Controls</i>	
IL-6 (pg/mL)	3.3 ± 2.5	$0.01 - 11.5$ ³⁸	
IL-18 (pg/mL)	274.2 ± 147.5	$80 - 120^{39}$	
hs-CRP (mg/dL)	3.6 ± 4.6	$< 0.3 \frac{40}{10}$	
TNF α (pg/mL)	1.4 ± 0.7	$0 - 2.2$	
		Legend: ± represents Mean and Standard Deviation; IL: Interleukin; CRP: C-reactive protein; TNF: Tumor Necrosis	

Table III. Comparison of inflammatory marker levels in Study Subjects and Healthy Controls.

Factor. Study Cohort N=25. *Healthy controls from published literature

Figure 1. Negative relationship between Lp(a) levels and *wIS*

Legend: Lp(a): Lipoprotein(a); *wIS*: weighted Isoform Size.

-
-
-
-

Figure 2. Apo(a) size distribution by Lp(a) level quartiles (nmol/L)

percentages of study subjects and absolute numbers in ().

1 ¹**Supplemental Data**

2

Supplemental Table I. Individual Subject Data 4

5 Legend: wIS – weighted Isoform Size; SRRE – Self Reported Race/Ethnicity. B-Black, W-White, H-Hispanic. Large isoform ≥22, Small isoform <22. *Calculated LDL-C not reported (TG levels >400 mg/dL). Small isoform<22. *Calculated LDL-C not reported (TG levels >400 mg/dL).

2

⁸**Supplemental Figure 1.** Apo(a) weighted isoform sizes in re-operative patients

11 Legend: wIS – weighted Isoform Size, Subject Number (N) underwent re-operation at 3-6 months.

3 ¹³**Supplemental Figure 2.** ABALEAR study CONSORT flow diagram

14

¹⁵Legend: LE—lower extremity; US—ultrasound; ABI—ankle brachial index; N—sample number